Sukanta Jash

Dr. Sukanta Jash

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
EAEmmanuel Amabebe
Emmanuel Amabebe
ZHZheping Huang
Zheping Huang
SJSukanta Jash
Sukanta Jash
Balaji KrishnanBalaji Krishnan
Balaji Krishnan
SCShibin Cheng
Shibin Cheng
SSSurendra Sharma
Surendra Sharma
Preeclampsia (preE) is a severe multisystem hypertensive syndrome of pregnancy associated with ischemia/hypoxia, angiogenic imbalance, apolipoprotein E (ApoE)-mediated dyslipidemia, placental insufficiency, and inflammation at the maternal–fetal interface. Our recent data further suggest that preE is associated with impaired autophagy, vascular dysfunction, and proteinopathy/tauopathy disorder, similar to neurodegenerative diseases such as Alzheimer’s disease (AD), including the presence of the cis stereo-isoform of phosphorylated tau (cis P-tau), amyloid-β, and transthyretin in the placenta and circulation. This review provides an overview of the factors that may lead to the induction and accumulation of cis P-tau-like proteins by focusing on the inactivation of peptidyl-prolyl cis–trans isomerase (Pin1) that catalyzes the cis to trans isomerization of P-tau. We also highlighted the novel role of the Pin1-cis P-tau-ApoE axis in the development of preE, and propagation of cis P-tau-mediated abnormal protein aggregation (tauopathy) from the placenta to cerebral tissues later in life, leading to neurodegenerative conditions. In the case of preE, proteinopathy/tauopathy may interrupt trophoblast differentiation and induce cell death, similar to the events occurring in neurons. These events may eventually damage the endothelium and cause systemic features of disorders such as preE. Despite impressive research and therapeutic advances in both fields of preE and neurodegenerative diseases, further investigation of Pin1-cis P-tau and ApoE-related mechanistic underpinnings may unravel novel therapeutic options, and new transcriptional and proteomic markers. This review will also cover genetic polymorphisms in the ApoE alleles leading to dyslipidemia induction that may regulate the pathways causing preE or dementia-like features in the reproductive age or later in life, respectively.

22 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SJSukanta Jash
Sukanta Jash
JSJohn M Sedivy
John M Sedivy
The human placenta, a transient but vital organ, governs fetal development and maternal-fetal interactions, yet its study has been stymied by ethical and accessibility constraints. Stem cell biology has now revolutionized the capacity to model human placental development, in particular with the derivation of human trophoblast stem cells (hTSCs) and organoids. Classically, hTSCs have been derived from pluripotent stem cells (PSCs) such as ESCs or iPSCs, which, under defined culture signals, can be directed into trophoblast lineages by manipulation of master regulatory pathways including GATA3, TFAP2C, and BMP4. However, a quantum leap has come with pluripotency-independent reprogramming, where somatic cells (e.g., fibroblasts) are reprogrammed directly into hTSCs. By bypassing the pluripotent stage with these specific transcription factors and trophoblast-supporting conditions, this approach enhances the efficiency, safety, and disease modeling potential of hTSC derivation. An important advance underlying these improvements is the mapping of a global reprogramming roadmap. Multi-omic and lineage-tracing experiments have mapped the stepwise transcriptional and epigenetic conversions of fibroblasts to hTSCs, including sequential chromatin reconfiguration, trophoblast gene network activation, and repression of somatic signatures. These results identify major regulatory bottlenecks and intermediate states, improving reprogramming fidelity. The derivation of stem-cell-based trophoblast organoids now enables complex modeling of placental architecture, function, and disease susceptibility in vitro. These organoids accurately recapitulate placental barrier functions and immunological features, allowing for examinations of maternal-fetal health, pregnancy disorders, and placental infection response to viruses like cytomegalovirus and SARS-CoV-2. Looking ahead, the integration of reprogramming and organoid technologies will propel patient-specific and tailor-made models for personalized diagnostics, drug screening, and mechanism studies. As we unravel the molecular ballet of trophoblast induction, such discoveries have the potential to bridge basic translational gaps in reproductive biology and maternal-fetal medicine.

31 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SJSukanta Jash
Sukanta Jash
JSJohn M. Sedivy
John M. Sedivy
The human placenta is a temporary organ structured to optimize exchange between the maternal and fetal circulatory systems. Its fetal component consists of highly branched chorionic villi, which are anchored to the maternal uterine wall and project into the intervillous space. The outer surface of these villi is lined by a multinucleated, continuous layer called the syncytiotrophoblast, which is supported by an underlying layer of proliferative cytotrophoblast cells and the invasive extravillous trophoblast (EVT). This cellular bilayer forms a selective barrier that directly bathes in maternal blood, allowing for the efficient transfer of oxygen and nutrients while structurally preventing the direct mixing of maternal and fetal blood cells. Human placental studies have been stymied by ethical and accessibility constraints. Stem cell biology has now revolutionized the capacity to model human placental development, in particular with the derivation of human trophoblast stem cells (hTSCs) and organoids. Authentic, self-renewing human trophoblast stem cells (hTSCs) were first derived not from pluripotent stem cells but from primary tissue—first-trimester villous cytotrophoblasts and blastocysts. Derivation from human pluripotent stem cells (PSCs) followed only subsequently, along two principal routes: conversion of naive PSCs, which retain extraembryonic competence, and induction from primed PSCs, as well as by direct reprogramming of somatic cells to induced hTSCs. An important advance underlying these improvements is the mapping of a global reprogramming roadmap. Multi-omic and lineage-tracing experiments have mapped the stepwise transcriptional and epigenetic conversions of fibroblasts to hTSCs, including sequential chromatin reconfiguration, trophoblast gene network activation, and repression of somatic signatures. These results identify major regulatory bottlenecks and intermediate states, improving reprogramming fidelity. The derivation of stem-cell-based trophoblast organoids now enables complex modeling of placental architecture, function, and disease susceptibility in vitro. These organoids accurately recapitulate placental barrier functions and immunological features, allowing for examinations of maternal–fetal health, pregnancy disorders, and placental infection response to viruses like cytomegalovirus and SARS-CoV-2. Looking ahead, the integration of reprogramming and organoid technologies will propel patient-specific and tailor-made models for personalized diagnostics, drug screening, and mechanism studies. As we unravel the molecular ballet of trophoblast induction, such discoveries have the potential to bridge basic translational gaps in reproductive biology and maternal–fetal medicine.

2 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DŠDovydas Širvinskas
Dovydas Širvinskas
SJSukanta Jash
Sukanta Jash
Induced pluripotent stem cells (iPSCs) have revolutionized the research landscape for Alzheimer's disease (AD) and related dementias by providing human, patient-specific neuronal models for studying the genetic and phenotypic diversity of these disorders. This review aims to integrate the latest advances in iPSC-based modeling of AD and dementia across multiple levels of biological organization. After describing the principles of pluripotency, iPSC generation, and quality control (genetic integrity, pluripotency assessment, long-term stability) the review will compare 2D monolayer culture with 3D organoid-based systems regarding their ability to model amyloid-beta, tau, and neuroinflammatory aspects of AD and dementia. The development of global stem cell biobanks and large iPSC collections with genetic diversity will be highlighted as an essential tool for dissecting the complex interplay of multiple genetic risk factors, ethnicity-based differences, and genotype-phenotype correlations. The review will discuss the use of genome editing technology, such as CRISPR/Cas9, for studying the effect of specific AD risk and protective variants in neurons and glial cells, and their implications for cell type-specific roles in neurodegeneration and neuroinflammation. We will highlight the challenges and limitations of iPSCs, such as cellular immaturity, loss of aging signatures, limited vascularization, and batch-to-batch differences, while noting the latest advances in partial/direct reprogramming, biomaterials science, and AI-based phenotypic analysis. Finally, the review will cover the expanding use of iPSC-based systems for high-content screening, functional therapeutic target validation, biomarker discovery, and development, and provide an overview of the future prospects for “clinical-trials-in-a-dish” and precision medicine for AD and other dementia disorders.